Eyebiotech Ltd

HOLBORN, LONDON, X0 · Founded 2021 · CIK 0001878733 · Biotech · Acquired

Therapeutic molecules targeting the Wnt pathway to restore blood-retinal barrier integrity in retinal vascular diseases

merck.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$486
1 Form D · Aug 2021
62 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$486
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2682THINK THERAPEUTICS, INC.——
2683Integrated Biotherapeutic Vaccines, Inc.—$3K
2684Ironfist Therapeutics, Inc.—$2K
2685Eyebiotech Ltd—$486
2686RevOpsis Holdings LLC—$1
2687ARTIAM BIO INC.——
2688RegenX LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Catherine BinghamDirector
  • James CostineDirector
  • David GuyerExecutive Officer
  • Michael RossExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.